Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Bright and Ultrafast Photoelectron Emission from Aligned Single-Wall Carbon Nanotubes through Multiphoton Exciton Resonance.

Green ME, Bas DA, Yao HY, Gengler JJ, Headrick RJ, Back TC, Urbas AM, Pasquali M, Kono J, Her TH.

Nano Lett. 2019 Jan 9;19(1):158-164. doi: 10.1021/acs.nanolett.8b03564. Epub 2018 Dec 17.

PMID:
30484322
2.

Corrigendum to Work Function Characterization of the Directionally Solidified LaB6--VB2 Eutectic [Ultramicroscopy 183 (2017) 67-71].

Back TC, Schmid AK, Fairchild SB, Boeckl JJ, Cahay M, Derkink F, Gong C, Sayir A.

Ultramicroscopy. 2018 May;188:102. doi: 10.1016/j.ultramic.2018.03.027. No abstract available.

PMID:
29655417
3.

Work function characterization of directionally solidified LaB6-VB2 eutectic.

Back TC, Schmid AK, Fairchild SB, Boeckl JJ, Cahay M, Derkink F, Chen G, Sayir A.

Ultramicroscopy. 2017 Dec;183:67-71. doi: 10.1016/j.ultramic.2017.05.006. Epub 2017 May 10. Erratum in: Ultramicroscopy. 2018 May;188:102.

PMID:
28522243
4.

Gaseous product mixture from Fischer-Tropsch synthesis as an efficient carbon feedstock for low temperature CVD growth of carbon nanotube carpets.

Almkhelfe H, Carpena-Núñez J, Back TC, Amama PB.

Nanoscale. 2016 Jul 21;8(27):13476-87. doi: 10.1039/c6nr03679a. Epub 2016 Jun 29.

PMID:
27353432
5.

Morphology dependent field emission of acid-spun carbon nanotube fibers.

Fairchild SB, Boeckl J, Back TC, Ferguson JB, Koerner H, Murray PT, Maruyama B, Lange MA, Cahay MM, Behabtu N, Young CC, Pasquali M, Lockwood NP, Averett KL, Gruen G, Tsentalovich DE.

Nanotechnology. 2015 Mar 13;26(10):105706. doi: 10.1088/0957-4484/26/10/105706. Epub 2015 Feb 19.

PMID:
25694166
6.

Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.

Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, Lee DH, Subleski J, Chan T, Weiss JM, Back TC, Yanaga K, Hanna N, Alexander HR, Maitra A, Hussain SP.

Int J Cancer. 2013 Feb 15;132(4):785-94. doi: 10.1002/ijc.27736.

7.

High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.

Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, Hixon JA, Back TC, Wei JS, Patidar R, Song Y, Hurd L, Tsokos M, Lai EW, Eisenhofer G, Weiss W, Khan J, Wigginton JM.

Cancer Invest. 2012 Jun;30(5):343-63. doi: 10.3109/07357907.2012.664670.

PMID:
22571338
8.

Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.

Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, Wiltrout RH.

PLoS One. 2012;7(3):e33303. doi: 10.1371/journal.pone.0033303. Epub 2012 Mar 13.

9.

Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.

Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH.

Cancer Res. 2011 Apr 1;71(7):2718-27. doi: 10.1158/0008-5472.CAN-10-2705. Epub 2011 Feb 15.

10.

TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.

Subleski JJ, Hall VL, Wolfe TB, Scarzello AJ, Weiss JM, Chan T, Hodge DL, Back TC, Ortaldo JR, Wiltrout RH.

J Immunol. 2011 Jan 15;186(2):838-47. doi: 10.4049/jimmunol.1001735. Epub 2010 Dec 10.

11.

Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.

Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19455-60. doi: 10.1073/pnas.0909474106. Epub 2009 Nov 5.

12.

Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.

Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, Dai RM, Scheetz L, Lincoln E, Back TC, Powell D, Hurwitz AA, Sayers TJ, Kastelein R, Pavlakis GN, Felber BK, Trinchieri G, Wigginton JM.

J Immunol. 2009 Apr 1;182(7):4328-38. doi: 10.4049/jimmunol.0800471.

13.

IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.

Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR, Wiltrout RH, Welniak LA, Redelman D, Murphy WJ.

Nat Med. 2007 Mar;13(3):354-60. Epub 2007 Mar 4.

PMID:
17334371
14.

Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver.

Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH.

Cancer Res. 2006 Nov 15;66(22):11005-12.

15.

Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.

Khan T, Stauffer JK, Williams R, Hixon JA, Salcedo R, Lincoln E, Back TC, Powell D, Lockett S, Arnold AC, Sayers TJ, Wigginton JM.

J Immunol. 2006 May 15;176(10):6302-12.

16.

Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors.

Stauffer JK, Khan T, Salcedo R, Hixon JA, Lincoln E, Back TC, Wigginton JM.

J Immunother. 2006 Mar-Apr;29(2):151-64.

PMID:
16531816
17.

Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma.

Khan T, Hixon JA, Stauffer JK, Lincoln E, Back TC, Brenner J, Lockett S, Nagashima K, Powell D, Wigginton JM.

J Natl Cancer Inst. 2006 Feb 1;98(3):190-202.

PMID:
16449679
18.

IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.

Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM.

J Immunol. 2004 Dec 15;173(12):7170-82.

19.

Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.

Ma W, Tessarollo L, Hong SB, Baba M, Southon E, Back TC, Spence S, Lobe CG, Sharma N, Maher GW, Pack S, Vortmeyer AO, Guo C, Zbar B, Schmidt LS.

Cancer Res. 2003 Sep 1;63(17):5320-8.

20.

Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer.

Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH.

Apoptosis. 2003 Mar;8(2):151-60.

PMID:
12766475
21.
22.

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.

J Immunol. 2002 Apr 1;168(7):3484-92.

23.

Hematopoietic switch from lymphoid to granulocytic development in 3LL tumor-bearing mice.

Lee JK, Back TC, Komschlies KL, Ruscetti FW, Young HA, Wiltrout RH.

In Vivo. 2001 Jul-Aug;15(4):255-63.

PMID:
11695215
24.

Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype.

Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton JM, Wiltrout RH.

Cancer Res. 2001 Aug 15;61(16):6255-63.

25.

IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH.

J Clin Invest. 2001 Jul;108(1):51-62.

27.

IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells.

Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JM, Wiltrout RH.

J Immunol. 2000 Jan 1;164(1):231-9.

28.
29.

T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.

Siders WM, Wright PW, Hixon JA, Alvord WG, Back TC, Wiltrout RH, Fenton RG.

J Immunol. 1998 Jun 1;160(11):5465-74.

30.

Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination.

Wigginton JM, Komschlies KL, Green JE, Cox GW, Jorcyk CL, Back TC, Franco JL, Brunda MJ, Wiltrout RH.

Ann N Y Acad Sci. 1996 Oct 31;795:434-9. No abstract available.

PMID:
8958976
32.

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.

Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH.

J Natl Cancer Inst. 1996 Jan 3;88(1):38-43.

PMID:
8847724
33.
34.

Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.

Murphy WJ, Back TC, Conlon KC, Komschlies KL, Ortaldo JR, Sayers TJ, Wiltrout RH, Longo DL.

J Clin Invest. 1993 Oct;92(4):1918-24.

35.

Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.

Murphy WJ, Conlon KC, Sayers TJ, Wiltrout RH, Back TC, Ortaldo JR, Longo DL.

J Immunol. 1993 Apr 15;150(8 Pt 1):3634-42.

PMID:
8468492
36.

In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells.

Futami H, Pilaro AM, Gruys ME, Back TC, Young HA, Wiltrout RH.

Biotherapy. 1991;3(3):219-32.

PMID:
1906724
37.
38.

Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.

Wiltrout RH, Boyd MR, Back TC, Salup RR, Arthur JA, Hornung RL.

J Immunol. 1988 May 1;140(9):3261-5.

PMID:
3258894
39.

Regulation of bone marrow cell survival in short-term cultures: a new macrophage function.

Blasi E, Back TC, Stull SW, Varesio L.

Cell Immunol. 1987 Feb;104(2):334-42.

PMID:
3815535
40.

Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.

Salup RR, Back TC, Wiltrout RH.

J Immunol. 1987 Jan 15;138(2):641-7.

PMID:
3491854
41.

Therapeutic requirements for the successful treatment of murine renal carcinoma by adoptive chemoimmunotherapy.

Wiltrout RH, Mathieson BJ, Back TC, Salup RR.

Prog Clin Biol Res. 1987;244:17-25. No abstract available.

PMID:
3498946

Supplemental Content

Support Center